These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38632971)

  • 1. Re-188 lipiodol in hepatocellular carcinoma with portal vein thrombosis: a pilot study using novel chelating agent N-DEDC and its comparison with (A)HDD.
    Datta Gupta SS; Shamim SA; Gamanagatti S; Gupta P; Khan MA; Mallia MB; Chirayil V; Dash A; Bal C
    Nucl Med Commun; 2024 Jun; 45(6):510-518. PubMed ID: 38632971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma.
    Sundram F; Chau TC; Onkhuudai P; Bernal P; Padhy AK
    Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):250-7. PubMed ID: 15129708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical 188Re-HDD/lipiodol intra-arterial therapy based on tumor volume, in patients with solitary inoperable hepatocellular carcinoma.
    Shinto AS; Karuppusamy KK; Kurup RER; Pandiyan A; Jayaraj AV
    Nucl Med Commun; 2021 Jan; 42(1):43-50. PubMed ID: 32956248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma.
    De Ruyck K; Lambert B; Bacher K; Gemmel F; De Vos F; Vral A; de Ridder L; Dierckx RA; Thierens H
    J Nucl Med; 2004 Apr; 45(4):612-8. PubMed ID: 15073257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Objective Tumor Response of Hepatocellular Carcinoma Obtained by Transarterial Radioembolization with Iodine-131-Lipiodol Versus Transarterial Chemoembolization for Patients with and without Portal Venous Thrombosis: A Controlled Interventional Trial.
    Oliveira Ribeiro MC; Moda KA; Alvarez M; Koga KH; Moriguchi SM; Carvalho FC; Pinheiro RSN; Qi X; Romeiro FG
    Acad Radiol; 2024 May; 31(5):1839-1848. PubMed ID: 38016824
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kumar N; Gupta P; Shamim SA; Chirayil V; Subramanian S; Mallia MB; Bal C
    World J Nucl Med; 2023 Jun; 22(2):114-123. PubMed ID: 37223628
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma. A single-center study based on a long-term follow-up.
    Ahmadzadehfar H; Habibi E; Ezziddin S; Wilhelm K; Fimmers R; Spengler U; Palmedo H; Strunk H; Schild HH; Biersack HJ; Risse J
    Nuklearmedizin; 2014; 53(2):46-53. PubMed ID: 24468919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis.
    Lambert B; Bacher K; De Keukeleire K; Smeets P; Colle I; Jeong JM; Thierens H; Troisi R; De Vos F; Van de Wiele C
    J Nucl Med; 2005 Aug; 46(8):1326-32. PubMed ID: 16085590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years' experience.
    Lintia-Gaultier A; Perret C; Ansquer C; Eugène T; Kraeber-Bodéré F; Frampas E
    Nucl Med Commun; 2013 Jul; 34(7):674-81. PubMed ID: 23587835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial.
    Kumar A; Srivastava DN; Chau TT; Long HD; Bal C; Chandra P; Chien le T; Hoa NV; Thulkar S; Sharma S; Tam le H; Xuan TQ; Canh NX; Pant GS; Bandopadhyaya GP
    Radiology; 2007 May; 243(2):509-19. PubMed ID: 17456873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol.
    Banka VK; Moon SH; Jeong JM; Seelam SR; Lee YS; Kim YJ; Lee DS; Chung JK
    Nucl Med Biol; 2015 Mar; 42(3):317-22. PubMed ID: 25537725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.
    Lambert B; Bacher K; Defreyne L; Gemmel F; Van Vlierberghe H; Jeong JM; Dierckx RA; Van de Wiele C; Thierens H; De Vos F
    J Nucl Med; 2005 Jan; 46(1):60-6. PubMed ID: 15632035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study.
    Lambert B; Bacher K; Defreyne L; Van Vlierberghe H; Jeong JM; Wang RF; van Meerbeeck J; Smeets P; Troisi R; Thierens H; De Vos F; Van de Wiele C
    Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):344-52. PubMed ID: 16333675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience.
    Chen KT; Tsai KF; Leung HWC; Chan ALF; Wang SY; Liang HL; Tang SY; Chou CK; Chen HY; Chan SH; Li MF
    Medicina (Kaunas); 2021 Jul; 57(8):. PubMed ID: 34440985
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of multiple intrahepatic recurrences after radiofrequency ablation of hepatocellular carcinoma with rhenium-188-HDD-lipiodol.
    Kumar A; Bal C; Srivastava DN; Thulkar SP; Sharma S; Acharya SK; Duttagupta S
    Eur J Gastroenterol Hepatol; 2006 Feb; 18(2):219-23. PubMed ID: 16394805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery: Interim results of a prospective study.
    Dutta D; Tatineni T; Yarlagadda S; Gupte A; Reddy SK; Madhavan R; Nair H; Sasidharan A; Kannan R; Pottayil SG; Holla R; Sudhindran S
    Indian J Gastroenterol; 2021 Aug; 40(4):389-401. PubMed ID: 34694581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma.
    Boschi A; Uccelli L; Duatti A; Colamussi P; Cittanti C; Filice A; Rose AH; Martindale AA; Claringbold PG; Kearney D; Galeotti R; Turner JH; Giganti M
    Nucl Med Commun; 2004 Jul; 25(7):691-9. PubMed ID: 15208496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
    Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
    Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of transarterial chemoembolization in Egyptian patients with hepatocellular carcinoma and branch portal vein thrombosis.
    Abdella H; Shaker MK; Montasser IF; Sobhi M; Aly H; Sayed A; Saleh S; El Dorry A
    Indian J Gastroenterol; 2018 Mar; 37(2):127-132. PubMed ID: 29532323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.